DLBCL
Conference Coverage
Chronic GVHD therapies offer hope for treating refractory disease
From the Journals
Prognostic gene signature identifies high- vs. low-risk DLBCL patients
The researchers calculated risk scores using their prognostic gene set in three additional published DLBCL studies.
Conference Coverage
Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies
Conference Coverage
Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHL
Conference Coverage
CAR T for all R/R DLBCL patients: The jury is still out
Feature
Seven things to know about new lymphoma drug tafasitamab
Conference Coverage
Survey quantifies COVID-19’s impact on oncology
Oncologists detail how COVID-19 has impacted care, caregivers, continuing medical education, and clinical trials.
News
FDA approves new drug for diffuse large B-cell lymphoma
From the Journals
HSCT or systemic treatment should be offered to HIV+ patients with lymphoma
News
FDA approves selinexor for relapsed/refractory DLBCL
Conference Coverage
Adding avadomide shows promise for newly diagnosed DLBCL